CAS 475207-59-1
:Nexavar
Descripción:
Nexavar, con el número CAS 475207-59-1, es el nombre comercial de sorafenib, un inhibidor de la tirosina quinasa de pequeñas moléculas utilizado principalmente en el tratamiento del cáncer. Se caracteriza por su capacidad para inhibir múltiples quinasas involucradas en la proliferación de células tumorales y la angiogénesis, incluyendo quinasas Raf y quinasas de receptor de tirosina como VEGFR y PDGFR. Sorafenib se administra típicamente por vía oral y es conocido por su papel en el tratamiento del carcinoma de células renales avanzado y el carcinoma hepatocelular. El compuesto es un sólido de color amarillo pálido a blanco sucio, con una fórmula molecular que incluye carbono, hidrógeno, nitrógeno, oxígeno y flúor. Su mecanismo de acción implica interrumpir las vías de señalización que promueven el crecimiento de células cancerosas y la formación de vasos sanguíneos, ralentizando así la progresión del tumor. Nexavar a menudo se asocia con efectos secundarios como fatiga, diarrea y reacciones cutáneas, que son consideraciones importantes en la gestión del paciente. En general, sorafenib representa un avance significativo en las terapias dirigidas contra el cáncer, ofreciendo un enfoque estratégico para combatir malignidades específicas.
Fórmula:C21H16ClF3N4O3·C7H8SO3
InChI:InChI=1S/C21H16ClF3N4O3.C7H8O3S/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25;1-6-2-4-7(5-3-6)11(8,9)10/h2-11H,1H3,(H,26,30)(H2,28,29,31);2-5H,1H3,(H,8,9,10)
Clave InChI:InChIKey=IVDHYUQIDRJSTI-UHFFFAOYSA-N
SMILES:O(C=1C=C(C(NC)=O)N=CC1)C2=CC=C(NC(NC3=CC(C(F)(F)F)=C(Cl)C=C3)=O)C=C2.S(=O)(=O)(O)C1=CC=C(C)C=C1
Sinónimos:- 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1)
- 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, mono(4-methylbenzenesulfonate)
- 4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide monomethanesulfonate
- BAY 43-9006 mono-p-tosylate
- Bay 54-9085
- N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea Tolsylate
- Nexavar
- Sorafenib TsOH salt
- Sorafenib p-toluenesulfonate
- Sorafenib-D3
- Sorafenib tosylate
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Encontrado 19 productos.
Sorafenib Tosylate
CAS:Fórmula:C21H16ClF3N4O3·C7H8O3SPureza:>98.0%(T)(HPLC)Forma y color:White to Light yellow powder to crystalPeso molecular:637.03Sorafenib Tosylate
CAS:Compounds containing an unfused pyridine ring in the structure, nesoiFórmula:C21H16ClF3N4O3·C7H8O3SForma y color:White Brown PowderPeso molecular:636.105724-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide; 4-methylbenzene-1-sulfonic acid
CAS:Fórmula:C28H24ClF3N4O6SPureza:98%Forma y color:SolidPeso molecular:637.0266Sorafenib tosylate
CAS:<p>Sorafenib tosylate (Bay 43-9006) is a potent multikinase inhibitor (IC50s: 6/20/22 nM for Raf-1/VEGFR-3/B-Raf).</p>Fórmula:C21H16ClF3N4O3·C7H8O3SPureza:99.24% - 99.94%Forma y color:White To Off-White Crystalline PowderPeso molecular:637.03Sorafenib tosylate
CAS:Fórmula:C21H16ClF3N4O3·C7H8O3SPureza:≥ 98.0% (dried basis)Forma y color:White, off-white or pale yellow-brown powderPeso molecular:637.03Sorafenib Tosylate
CAS:Fórmula:C21H16ClF3N4O3·C7H8O3SForma y color:Off-White SolidPeso molecular:464.83 172.20Sorafenib Tosylate
CAS:Producto controladoFórmula:C21H16ClF3N4O3·C7H8O3SForma y color:NeatPeso molecular:637.03Sorafenib tosylate
CAS:<p>Sorafenib tosylate</p>Fórmula:C21H16ClF3N4O3·C7H8O3SPureza:99%Forma y color: off-white solidPeso molecular:637.03g/molSorafenib Tosylate
CAS:Producto controladoFórmula:C21H16ClF3N4O3·C7H8O3SForma y color:NeatPeso molecular:637.03Sorafenib tosylate
CAS:<p>Sorafenib is a drug that belongs to the class of multikinase inhibitors. It inhibits a number of kinases, including the Mcl-1 protein, which is involved in apoptosis along with blocking picolinic acid (PA), an endogenous metabolite involved in apoptosis signal transduction. Sorafenib also binds to epidermal growth factor receptor (EGFR) on the surface of cancer cells, inhibiting the production of proteins that are required for angiogenesis, thus blocking the formation of new blood vessels. Sorafenib may also inhibit P-glycoprotein (Pgp) activity. Overall, these cytotoxic effects give Sorafenib anti-tumor properties, inhibiting angiogenesis and cellular transformation, which are the two main processes of tumor growth and metastasis. Sorafenib tosylate has been shown to be effective against a range of solid tumors such as breast, prostate and lung cancers and is also used for the treatment of metastatic colorectal cancer and renal cell carcinoma. A combination therapy group found that sorafenib was more effective when used with interferon alfa-2b for the treatment of advanced renal cell carcinoma. Sorafenib also has the potential for drug interactions with other drugs that are metabolized by cytochrome P450 enzymes.</p>Fórmula:C21H16ClF3N4O3•C7H8O3SPureza:Min. 95%Forma y color:Off-White PowderPeso molecular:637.03 g/molSorafenib tosylate - Bio-X ™
CAS:<p>Sorafenib is a drug that belongs to the class of multikinase inhibitors. It inhibits a number of kinases, including the Mcl-1 protein, which is involved in apoptosis along with blocking picolinic acid (PA), an endogenous metabolite involved in apoptosis signal transduction. Sorafenib also binds to epidermal growth factor receptor (EGFR) on the surface of cancer cells, inhibiting the production of proteins that are required for angiogenesis, thus blocking the formation of new blood vessels. Sorafenib may also inhibit P-glycoprotein (Pgp) activity. Overall, these cytotoxic effects give Sorafenib anti-tumor properties, inhibiting angiogenesis and cellular transformation, which are the two main processes of tumor growth and metastasis. Sorafenib tosylate has been shown to be effective against a range of solid tumors such as breast, prostate and lung cancers and is also used for the treatment of metastatic colorectal cancer and renal cell carcinoma. A combination therapy group found that sorafenib was more effective when used with interferon alfa-2b for the treatment of advanced renal cell carcinoma. Sorafenib tosylate also has the potential for drug interactions with other drugs that are metabolized by cytochrome P450 enzymes.<br>Sorafenib tosylate is part of our Bio-X ™ Range. These products are aimed at life science researchers who need high quality ready to use products for assay development, screening or other R&D work. With a solubility datasheet and convenient vials, all of our Bio-X ™ products are in stock across our global warehouses for rapid delivery and ease of use.</p>Fórmula:C21H16ClF3N4O3•C7H8O3SPureza:Min. 95%Forma y color:PowderPeso molecular:637.03 g/molSorafenib, p-Toluenesulfonate Salt
CAS:Fórmula:C35H30F3N7O4SPureza:98%Forma y color:SolidPeso molecular:701.73
![4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide…](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FIN%2Fthumb%2FDA0035M4.jpg&w=3840&q=75)
